Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.

Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.